



# EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT

MARTÍNEZ-OREA G<sup>1,2</sup>, GARCÍA-GONZÁLEZ C<sup>1</sup>, FUENTES-HIDALGO F<sup>1</sup>, BONILLA-PEÑARRUBIA R<sup>1</sup>, CANO-CUENCA N<sup>1</sup>, RODRÍGUEZ-LUCENA FJ<sup>1</sup>.

<sup>1</sup>Hospital Pharmacy – Hospital Vega Baja de Orihuela, 03314 Alicante, Spain  
<sup>2</sup>Email: martinez\_gabriel@gva.es

## Background and Importance


**Isatuximab** is a new IgG1 kappa monoclonal antibody directed against CD38, which has been approved by the EMA and FDA in combination with carfilzomib and dexamethasone (Isa-Kd) in patients with **multiple myeloma**

## Aim and Objectives

To describe the **efficacy** and **safety** of the Isa-Kd combination in a patient with multiple myeloma refractory to previous lines

## Materials and Methods

Retrospective clinical case:



2021



**Efficacy**

Progression-free survival

**Safety**

Absence of adverse effects

## Results

- 55 years old male
- Weight = 69kg ; Height = 173cm
- Multiple myeloma refractory to 4 prior lines of treatment
- Patient not eligible for ASCT due to psychiatric illness

**Efficacy**

Disease progression after **4 months**


**Safety**

No adverse reactions were observed during infusion

Asthenia after administration



**Isatuximab** (10mg/kg)



**Carfilzomib** (56mg/m<sup>2</sup>)

## Conclusion

Isa-Kd administration in our patient achieved a progression-free survival of **4 months** and has been shown to be **safe** in the treatment of refractory multiple myeloma.